News | September 07, 2009

Medipattern Closes on a $2.5M Financial Injection

September 8, 2009 - The Medipattern Corp., an imaging workflow software developer, announced last week it closed a non-brokered private placement (the "Offering") of 2,500,000 common shares in the capital stock of the company at $0.20 per common share, for gross proceeds of $500,000.00 to the company.

As was the case for the $2 million raised under the same terms earlier in the summer, proceeds from the Offering will be used for general working capital purposes of the company, including the further development of its Vascular iQ initiative and to continue building on the success of its B-CAD-FOR-LIFE solution.
The common shares issued under the Offering will be subject to a four month and one day resale restriction commencing from the date of issuance. The Offering is subject to TSX Venture Exchange final acceptance of the requisite regulatory filings.

Medipattern offers B-CAD advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza CAD technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective.

For more information: www.medipattern.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
iCAD Announces Positive Clinical Results for Artificial Intelligence Tomosynthesis Technology
News | Mammography | October 11, 2018
iCAD Inc. announced positive clinical results of its new digital breast tomosynthesis (DBT) cancer detection software,...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Riverain Technologies Issued U.S. Patent for Vessel Suppression Technology
News | Computed Tomography (CT) | June 14, 2018
Riverain Technologies announced that the United States Patent and Trademark Office (USPTO) has awarded the company a...
FDA Issues Proposed Order to Reclassify Certain Radiological Medical Image Analyzers
News | Computer-Aided Detection Software | June 01, 2018
The U.S. Food and Drug Administration (FDA) is issuing a proposed order to reclassify certain radiological medical...
Median Technologies and the Nice University Hospital to Use AI in Lung Cancer Screening
News | Artificial Intelligence | March 15, 2018
March 15, 2018 – Median Technologies, the industry-leading Imaging Phenomics Company and the Nice University Hospital
FDA Clears First AI-Powered Clinical Decision Support Software for Stroke
Technology | Clinical Decision Support | February 14, 2018
The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first ...